Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2025BloodOpen Access

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAjai ChariGreat Ormond Street HospitalNDNiels W.C.J. van de DonkNational Cancer CenterBDBhagirathbhai DholariaVanderbilt University Medical Center

Discussion

Loading...

Member takes

Implication

Phase 1b TRIMM-2 trial shows enhanced efficacy for talquetamab plus daratumumab in multiple myeloma, suggesting potential benefits over monotherapy.

Key Points

  • Talquetamab plus daratumumab demonstrates a 71.4% response in the QW cohort and an 82.4% response in the Q2W cohort.
  • Median progression-free survival was observed at 23.3 months for the QW cohort and 21.2 months for the Q2W cohort.
  • Among the 65 patients evaluated, 81.5% experienced grade 3/4 adverse events, including cytokine release syndrome.
  • Pharmacodynamic results indicate that daratumumab reduces immunosuppressive cells, enhancing the effect of talquetamab.

Cite This Study

Chari et al. (2025) studied this question.

synapsesocial.com/papers/68d43d83713b0b5dfea7dd83https://doi.org/10.1182/blood.2025029360
View Full Paper
Ask AI
Bookmark
Share